French Institute of Health and Medical Research-ko ikertzaileekin lankidetzan egindako argitalpenak (25)

2017

  1. HIV-1 infection in persons homozygous for CCR5-Δ32 allele: The next case and the review

    AIDS Reviews, Vol. 19, Núm. 4, pp. 219-230

2016

  1. Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: Raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART

    Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 4, pp. 1056-1062

  2. Infection-related and -unrelated malignancies, HIV and the aging population

    HIV Medicine, Vol. 17, Núm. 8, pp. 590-600

  3. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study

    Medicine (United States), Vol. 95, Núm. 40

  4. The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment

    AIDS, Vol. 30, Núm. 6, pp. 879-888

2015

  1. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study

    HIV Medicine, Vol. 16, Núm. 9, pp. 533-543

  2. Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4 + T-cell recovery once HIV-1 suppression is achieved?

    AIDS, Vol. 29, Núm. 17, pp. 2323-2333

  3. Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration

    Journal of Acquired Immune Deficiency Syndromes, Vol. 69, Núm. 3, pp. 348-354

  4. Liver-related death among HIV/hepatitis C virus-co-infected individuals: Implications for the era of directly acting antivirals

    AIDS, Vol. 29, Núm. 10, pp. 1205-1215

2014

  1. A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

    Infection, Vol. 42, Núm. 4, pp. 757-762

  2. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions

    Neurology, Vol. 83, Núm. 2, pp. 134-141

  3. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study

    BMC Nephrology, Vol. 15, Núm. 1

  4. Evaluation of rapid progressors in HIV infection as an extreme phenotype

    Journal of Acquired Immune Deficiency Syndromes, Vol. 67, Núm. 1, pp. 15-21

  5. Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe

    PLoS ONE, Vol. 9, Núm. 1

  6. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

2013

  1. Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients

    PLoS ONE, Vol. 8, Núm. 5

  2. Insurability of HIV-positive people treated with antiretroviral therapy in Europe: Collaborative analysis of HIV cohort studies

    AIDS, Vol. 27, Núm. 10, pp. 1641-1655

  3. Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)

    PLoS Medicine, Vol. 10, Núm. 9

  4. Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection

    PLoS ONE, Vol. 8, Núm. 11

2012

  1. All-cause and liver-related mortality in HIV positive subjects compared to the general population: Differences by HCV co-infection

    Journal of Hepatology, Vol. 57, Núm. 4, pp. 743-751